Commonwealth Equity Services
DNLI icon

Commonwealth Equity Services’s Denali Therapeutics DNLI Stock Holding History

Commonwealth Equity Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,636
Closed -$206K – 3729
2021
Q4 		$206K Buy
4,636
+472
+11% +$22.4K ﹤0.01% 3280
2021
Q3 		$210K Buy
4,164
+195
+5% +$11K ﹤0.01% 3235
2021
Q2 		$311K Hold
3,969
– – ﹤0.01% 2861
2021
Q1 		$226K Hold
3,969
– – ﹤0.01% 3027
2020
Q4 		$332K Buy
+3,969
New +$240K ﹤0.01% 2481

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Commonwealth Equity Services's DNLI Position: Q1 2022 in Review

Commonwealth Equity Services sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 4,636 shares — an estimated $206K sold.

Commonwealth Equity Services first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $332K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Commonwealth Equity Services reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 4,636 Denali Therapeutics shares in Q1 2022, an estimated $206K.
  • Commonwealth Equity Services first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
  • Commonwealth Equity Services's Denali Therapeutics position peaked at $332K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Commonwealth Equity Services's 13F filing for Q1 2022, filed 4 May 2022.